drugset / Trial / NCT01990196
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Phase 2
Active not recruiting
45 enrolled
Jonsson Comprehensive Cancer Center
Astellas Pharma Inc · collabGlaxoSmithKline · collabMedivation, Inc. · collabNovartis · collabProstate Cancer Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated with hormone therapy plus drugs that directly target cancer cells.
Timeline
- Start
- 2014-09-23
- Primary completion
- 2024-09-23
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Trametinib | Small molecule | 2 mg | Oral |
| Comparator | dasatinib anhydrous | Small molecule | 100 mg | Oral |
| Comparator | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Comparator | Enzalutamide | Other / unclassified | 160 mg | Oral |